SEC Form 4/A · accession 0001349929-17-000067
CANCER GENETICS, INC · CGIX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
This is an amendment (Form 4/A). It replaces an earlier filing for the same period.
Reporting owner
John Pappajohn
Director · 10% Owner
Period of report
Aug 17, 2017
Accepted (ET)
Aug 18, 2017 · 4:32 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001349929
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, par value $0.0001 per shareF1 | Aug 17, 2017 | P | 66,185 | $3.235 | A | 2,608,704 | D | |
| Common Stock, par value $0.0001 per shareF2,F3 | Aug 18, 2017 | P | 20,000 | $3.278 | A | 2,628,704 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F11. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.15 to $3.30, inclusive. The reporting person undertakes to provide Cancer Genetics, Inc., any security holder of Cancer Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4.
- F2The original Form 4, filed on August 18, 2017 is amended to correctly reflect the transaction date. No other changes have been made to the original Form 4.
- F31. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.25 to $3.30, inclusive. The reporting person undertakes to provide Cancer Genetics, Inc., any security holder of Cancer Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (2) to this Form 4.